Project Grant R01DK137971
Award Date
8/15/24
Completion Date
5/31/29
Dollars Obligated
$622K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award of $1,614,573 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to identify the earliest molecular and genetic events underlying the transition from non-dysplastic to dysplastic Barrett's esophagus. The research team at the University of Pennsylvania will leverage single-cell RNA sequencing, mitochondrial mutation-based lineage...
This $477,151 Project Grant was awarded on September 1, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI). The purpose of the grant is to study how neoplasia-derived extracellular vesicle microRNAs can promote DNA damage and carcinogenesis in Barrett's esophagus, with the goal of identifying novel targets for chemical ablation. The grant includes two sub-awards...
The federal Project Grant award R01DK141535, in the amount of $465,155.00, was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research aimed at understanding the role of the SRCAP gene in therapy-related clonal hematopoiesis and the development of therapy-related myeloid neoplasms, which are a serious complication of cancer treatment. The...
This $485,558 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to characterize a novel glutathione-related metabolic pathway that drives metastatic outgrowth in pancreatic ductal adenocarcinoma (PDA). The key objectives are to molecularly characterize two pathway factors, GSTT1 and SLC38A4, that are specifically expressed...
This federal Project Grant award, valued at $606,698.00 and awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of lysosomes in maintaining intestinal stem cells and their contribution to intestinal tumorigenesis. The key objectives of the project are to: 1) characterize the intestine-specific phenotypes of TFE3 and TFEB...
This federal Project Grant award, valued at $575,394.00 and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports a multi-ancestry genetic analysis of Type 1 Diabetes (T1D) and related conditions. The project aims to develop a multi-ancestry T1D polygenic risk score to better predict risk across diverse populations, as well as to identify genetic subtypes of T1D...
This federal Project Grant award of $533,907 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research on the role of TET3-mediated DNA oxidation in regulating intestinal epithelial cell (IEC) homeostasis and responses to inflammatory stressors. The research aims to elucidate how environmental cues, including the gut microbiome and inflammatory agents, impact DNA...
This federal Project Grant award in the amount of $623,589 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the mechanisms through which the Aryl Hydrocarbon Receptor (AhR) mediates both protective and detrimental effects on esophageal inflammation in eosinophilic esophagitis (EoE), an allergic disease of the esophagus. The research...
This $547,413 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to characterize the role of double-stranded RNA (dsRNA) signaling in gastric pre-neoplasia. The objective is to establish how dsRNA signaling contributes to the development of pyloric metaplasia, a precancerous gastric condition. The research will leverage genetically...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new therapeutics targeting FGFR2 alterations in gastroesophageal (GEA) cancer. The $716,314 award, active from July 2024 to June 2029, supports the following key efforts: The development and testing of FGFR2 biparatopic antibody-drug conjugates (ADCs) and naked biparatopic antibodies in FGFR2-altered GEA cell lines and xenograft models, including assessment of efficacy compared...